WASHINGTON, April 1 (TNSFR) -- The U.S. Department of Health and Human Services National Institutes of Health National Eye Institute is reviewing a proposal to grant an exclusive patent license to Perpetual Biosciences Inc., New York. This agreement would allow the company to use specific inventions aimed at treating human eye diseases through peptide therapeutics.

The technology involves chemically synthesized peptide fragments derived from a naturally occurring protein known as pi . . .

Click here for more information about our products